A phase IB open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC)

Project: Research

Project Description

NMA Reference Number: HREC/17/MonH/92
Monash Health HREC Ref: RES-17-0000-163A
StatusActive
Effective start/end date4/04/19 → 3/04/24
View all
View less

Keywords

  • clinical trial
  • phase 1 study
  • prostrate cancer
  • treatment efficacy
  • clinical trial
  • phase 1 study
  • prostrate cancer
  • treatment efficacy
  • clinical trial
  • phase 1 study
  • prostrate cancer
  • treatment efficacy